• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Video

Dermatology Times Chief Medical Editor Weighs in On Black Box Warning for JAK Inhibitors

Author(s):

Morgan Petronelli

In this exclusive video interview, Zoe Diana Draelos, MD, Dermatology Times chief medical editor, weighs in on the recent Black Box Warning issued by the FDA to certain JAK inhibitors.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!
Related Videos
Related Content
FDA Approves Dupilumab for Adolescents and Adults With H1 Antihistamine-Refractory Chronic Spontaneous Urticaria
April 18th 2025

FDA Approves Dupilumab for Adolescents and Adults With H1 Antihistamine-Refractory Chronic Spontaneous Urticaria

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics
September 23rd 2021

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

Exploring Off-Label Uses of Topical JAK Inhibitors
April 11th 2025

Exploring Off-Label Uses of Topical JAK Inhibitors

The Cutaneous Connection
September 2nd 2021

The Cutaneous Connection: Episode 30- Impact of the JAK Inhibitor Approval Delays

Quoin Files US Patent Applications for Rare Disease Treatments
March 25th 2025

Quoin Files US Patent Applications for Rare Disease Treatments

Potential Treatments for TSW Identified in NIH Study
March 18th 2025

Potential Treatments for TSW Identified in NIH Study

© 2025 MJH Life Sciences

All rights reserved.